Francesco Liotta, Francesco Annunziato, Sergio Castellani, Maria Boddi, Brunetto Alterini, Giovanni Castellini, Benedetta Mazzanti, Lorenzo Cosmi, Manlio Acquafresca, Filippo Bartalesi, Beatrice Dilaghi, Walter Dorigo, Gabriele Graziani, Benedetta Bartolozzi, Guido Bellandi, Giulia Carli, Alessandro Bartoloni, Aaron Fargion, Filippo Fassio, Paolo Fontanari, Giancarlo Landini, Eleonora A M Lucente, Stefano Michelagnoli, Carolina Orsi Battaglini, Grazia Panigada, Clara Pigozzi, Valentina Querci, Veronica Santarlasci, Paola Parronchi, Nicola Troisi, Cristiana Baggiore, Paola Romagnani, Edoardo Mannucci, Riccardo Saccardi, Carlo Pratesi, Gianfranco Gensini, Sergio Romagnani, Enrico Maggi
BACKGROUND: The therapeutic efficacy of bone marrow mononuclear cells (BM-MNC) autotransplantation in critical limb ischemia (CLI) has been reported. Variable proportions of circulating monocytes express low levels of CD34 (CD14+ CD34low cells) and behave in vitro as endothelial progenitor cells (EPCs). The aim of the present randomized clinical trial was to compare the safety and therapeutic effects of enriched circulating EPCs (ECEPCs) with BM-MNC administration.Methods and Results:ECEPCs (obtained from non-mobilized peripheral blood by immunomagnetic selection of CD14+ and CD34+ cells) or BM-MNC were injected into the gastrocnemius of the affected limb in 23 and 17 patients, respectively...
May 25, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society